Palavras-chave
Mostrar mais Palavras-chave
Índice
  1. 1. Estudo clínico
  2. 2. Documentação de rotina
  3. 3. Estudos de registo/coortes
  4. 4. Garantia da qualidade
  5. 5. Padrão de dados
  6. 6. Questionário do paciente
  7. 7. Especialidade médica
Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

3793 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

dbGaP phs000841 Tyrosine Kinase Mutations in Endometrial Cancer - pht004420.v1.p1

- 29/01/2025 - 5 Formulários, 1 Grupo de itens, 5 Elementos de dados, 1 Idioma
Grupo de itens: pht004420
Principal Investigator: Daphne W. Bell, PhD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA MeSH: Endometrial Carcinomas https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000841 The purpose of the original study was to search for somatic mutations in the tyrosine kinome of serous and clear cell endometrial carcinomas (human). The study was conducted in two phases. Phase 1: A mutation discovery screen, in which ~577 exons encoding the catalytic domains of 86 tyrosine kinases were PCR-amplified and bidirectionally Sanger sequenced from 24 serous, 11 clear cell, and 5 mixed histology endometrial tumors. This was followed by alignment of sequence reads to the human reference sequence and subsequent nucleotide variant calling to identify potential somatic (tumor-specific) mutations. Potential somatic mutations were confirmed by re-amplification and sequencing of the relevant tumor DNA as well as matched non-tumor ("normal") DNA from the same case. Phase 2: A mutation prevalence screen, in which the non-catalytic regions two tyrosine kinase genes, TNK2 and DDR1, were PCR-amplified and sequenced from the 40 discovery screen tumors, and all coding exons of TNK2 and DDR1 were PCR-amplified and sequenced from another 10 clear cell, 21 serous, and 41 endometrioid endometrial tumors, in an effort to identify additional somatic mutations in each gene. Exons encoding the exonuclease domain of POLE were also sequenced to document somatic mutations.

pht004421.v1.p1

1 Grupo de itens 4 Elementos de dados

pht004422.v1.p1

1 Grupo de itens 12 Elementos de dados

Eligibility

1 Grupo de itens 4 Elementos de dados

pht004419.v1.p1

1 Grupo de itens 3 Elementos de dados

register Finish Cancer Registry cancer - register

- 15/03/2021 - 1 Formulário, 6 Grupos de itens, 49 Elementos de dados, 2 Idiomas
Grupos de itens: CancerRegistry, Previous cancer, Current Neoplasm, Treatment, surgery, radiotherapy
Data set from the Finish cancer registry, with friendly permission (http://www.cancer.fi/syoparekisteri/en/registration/forms-and-instructions/)

dbGaP phs001152 Somatic Mutational Analysis by Exome Sequencing Endometrial Carcinosarcomas - Eligibility

- 14/06/2023 - 5 Formulários, 1 Grupo de itens, 4 Elementos de dados, 1 Idioma
Grupo de itens: IG.elig
Principal Investigator: Daphne W. Bell, PhD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA MeSH: Endometrial Neoplasms,Carcinosarcoma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001152 The purpose of this study was to identify somatic (tumor-specific) mutations in endometrial carcinosarcoma tumor exomes. The dataset was generated at the NIH Intramural Sequencing Center (NISC) and NHGRI by next generation sequencing the exomes of 14 de-identified primary tumor DNAs and matched non-tumor DNAs.

pht005534.v1.p1

1 Grupo de itens 3 Elementos de dados

pht005535.v1.p1

1 Grupo de itens 3 Elementos de dados

pht005536.v1.p1

1 Grupo de itens 2 Elementos de dados

pht005537.v1.p1

1 Grupo de itens 8 Elementos de dados

Breast Cancer NCT00433589 Treatment - Endocrine therapy - 2498727v1.0 - Endocrine therapy

- 09/01/2015 - 1 Formulário, 3 Grupos de itens, 14 Elementos de dados, 1 Idioma
Grupos de itens: Header, Endocrine therapy, Footer Module
Endocrine therapy Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=19677A9A-FFBD-2E6F-E044-0003BA3F9857

Endometrial Cancer NCT01210222 Pre-Study - GOG-0229L: Fast Fact Sheet for Protocol 0229L (Endometrium) - 3184152v1.0 - GOG-0229L: Fast Fact Sheet for Protocol 0229L (Endometrium)

- 17/09/2021 - 1 Formulário, 3 Grupos de itens, 88 Elementos de dados, 1 Idioma
Grupos de itens: Patient Information, Eligibility 1, Provide comments about this Fast Fact Sheet
GOG-0229L: Fast Fact Sheet for Protocol 0229L (Endometrium) AMG 386 in Treating Patients With Persistent or Recurrent Endometrial Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9A223983-7B94-E221-E040-BB89AD437E30

Endometrial Cancer NCT00265759 Registration - ACOSOG-Z1031 OPEN Registration Worksheet - 3014513v1.0 - ACOSOG-Z1031 OPEN Registration Worksheet

- 17/09/2021 - 1 Formulário, 6 Grupos de itens, 45 Elementos de dados, 1 Idioma
Grupos de itens: Header Module, Demography Section, General Information, Inclusion Criteria, Exclusion Criteria, Treatment Arm
ACOSOG-Z1031 OPEN Registration Worksheet Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=8036B060-D675-EB4B-E040-BB89AD434531

Endometrial Cancer NCT01225887 Pre-Study - GOG-0229K: Fast Fact Sheet for Protocol 0229-K (Endometrium) - 3183206v1.0 - GOG-0229K: Fast Fact Sheet for Protocol 0229-K (Endometrium)

- 17/09/2021 - 1 Formulário, 3 Grupos de itens, 91 Elementos de dados, 1 Idioma
Grupos de itens: Patient Information, Eligibility 1, Provide comments about this Fast Fact Sheet
GOG-0229K: Fast Fact Sheet for Protocol 0229-K (Endometrium) BIBF 1120 in Treating Patients With Recurrent or Persistent Endometrial Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=99D51BE9-A450-39B5-E040-BB89AD43255D

Endometrial Cancer NCT00265759 Registration - Z1031 Registration Worksheet Form - 2417050v1.0 - Z1031 Registration Worksheet Form

- 17/09/2021 - 1 Formulário, 9 Grupos de itens, 66 Elementos de dados, 1 Idioma
Grupos de itens: Header Module, Header, Patient Information, Correlative Studies and Specimen Banking , Inclusion Criteria, Exclusion Criteria, Eligibility/Performance Status, Clinical Stage, Primary Tumor Biopsy
Z1031 Registration Worksheet Form Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=02F0FC02-607A-58B8-E044-0003BA3F9857

dbGaP phs001127 Genomic Analysis of Paired Endometrial Cancer Primaries and Metastases - Eligibility

- 19/06/2023 - 5 Formulários, 1 Grupo de itens, 1 Elemento de dados, 1 Idioma
Grupo de itens: IG.elig
Principal Investigator: Rameen Beroukhim, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, USA, Brigham and Women's Hospital, Boston, MA, USA, Broad Institute of MIT and Harvard, Cambridge, MA, USA MeSH: Endometrial Neoplasms,Neoplasm Metastasis https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001127 Formation of metastases is the major cause of cancer related deaths. Recent studies have sequenced primary endometrial carcinomas yielding data for a single entity in the progression from the birth of a progenitor tumor cell to metastatic disease. However, the progression of these tumors to metastases has not been characterized. We performed whole-exome sequencing of 98 tumor biopsies including complex atypical hyperplasias, primary tumors and paired abdominopelvic metastases to survey the evolutionary landscape of endometrial cancer. We expanded and reanalyzed TCGA-data, identifying novel recurrent alterations in primary tumors, including mutations in the estrogen receptor cofactor *NRIP1* in 12% of patients. We found that likely driver events tended to be shared by primary and metastatic tissue-samples, with notable exceptions such as *ARID1A* mutations. Phylogenetic analyses in cases with multiple metastases indicated these metastases typically arose from one lineage of the primary tumor. These data indicate extensive genetic heterogeneity within endometrial cancers and relative homogeneity across metastatic sites.

pht005525.v1.p1

1 Grupo de itens 2 Elementos de dados

pht005526.v1.p1

1 Grupo de itens 3 Elementos de dados

pht005527.v1.p1

1 Grupo de itens 7 Elementos de dados

pht005528.v1.p1

1 Grupo de itens 5 Elementos de dados

dbGaP phs001153 Somatic Mutational Analysis by Exome Sequencing Late-Stage Endometrioid Endometrial Carcinoma - pht005695.v1.p1

- 05/06/2023 - 5 Formulários, 1 Grupo de itens, 3 Elementos de dados, 1 Idioma
Grupo de itens: pht005695
Principal Investigator: Daphne W. Bell, PhD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA MeSH: Endometrial Neoplasms,Carcinoma, Endometrioid https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001153 The purpose of this study was to identify somatic (tumor-specific) mutations in advanced stage endometrioid endometrial carcinoma tumor exomes. The dataset was generated at the NIH Intramural Sequencing Center (NISC) and NHGRI by next generation sequencing the exomes of 19 de-identified primary tumor DNAs, from advanced stage tumors, and matched non-tumor DNAs.

pht005696.v1.p1

1 Grupo de itens 2 Elementos de dados

pht005697.v1.p1

1 Grupo de itens 8 Elementos de dados

pht005694.v1.p1

1 Grupo de itens 3 Elementos de dados

Eligibility

1 Grupo de itens 5 Elementos de dados

Vital Signs Anal Cancer NCT00324415

- 31/07/2015 - 1 Formulário, 3 Grupos de itens, 13 Elementos de dados, 1 Idioma
Grupos de itens: Header module, Vital Signs, Comments
Anal Cancer NCT00324415 On-Study - AMC-045 Vital Signs Form (F20) - 2937179v1.0 Cisplatin, Fluorouracil, Cetuximab, and Radiation Therapy in Treating Patients With HIV and Stage I, Stage II, or Stage III Anal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=7285E88F-E0EF-C8EB-E040-BB89AD437ABB

Eligibility NCT00334295 Metastatic Endometrial Carcinoma - Eligibility

- 20/09/2021 - 1 Formulário, 2 Grupos de itens, 8 Elementos de dados, 2 Idiomas
Grupos de itens: Inclusion Criteria, Exclusion criteria
ODM derived from http://clinicaltrials.gov/ct2/show/NCT00334295?term=NCT00334295&rank=1

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial